ARTICANZ - Beta (ver 0.91)
Annotated Registry of Trials in Cancer, Australia and New Zealand Ed.
- Results - catype/medical-oncology/non-small-cell-lung/advanced-metastatic/her2/subsequent
Home
By cancer type
By drug class
By site
Data
FAQ
About
⚠
ARTICANZ provides informational content about cancer drug trials in Australia/NZ that is updated weekly but may not be completely accurate, and should not replace medical advice from qualified healthcare professionals. The platform is intended to be useful, providing information "as is" without warranties. Non-medical users must always consult healthcare providers for all clinical decisions.
Search results
Respiratory / Non small cell lung - Advanced/metastatic / HER2 / Subsequent
4
trial(s) found.
NCT06905197
Advanced
Phase 1
Recruiting
A Phase 1, Open-Label, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics, and Anti-tumor Efficacy of DZD6008 in Patients With Advanced Non-small Cell Lung Cancer (NSCLC) With EGFR Mutations (TIAN-SHAN1) (
DZ2023C0001
)
EGFR inhibitor,fourth generation
Non-small cell lung cancer
NSW
2050 - Camperdown - Chris O'Brien Lifehouse
2148 - Blacktown - Blacktown Hospital, Blacktown Cancer and Haematology Centre
NCT06816992
Advanced
Phase 1
Recruiting
Phase 1b Study of ORIC-114 in Combination with Amivantamab in Patients with EGFR Exon20 Insertion Mutant NSCLC (
ORIC-114-05
)
EGFR inhibitor,exon 20 selective
ERBB2 inhibitor,exon 20 selective
bispecific cMET/EGFR antibody
Non-small cell lung cancer
Solid tumour
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
NCT06625775
Advanced
Phase 1
Recruiting
A Phase 1a/1b Open-Label Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of BBO-10203 in Subjects With Advanced Solid Tumors (The BREAKER-101 Study) (
TBBO10203-101
)
PI3K alpha-RAS breaker
Breast cancer
Colorectal cancer
HER2-negative breast cancer
HER2-positive breast cancer
Non-small cell lung cancer
RAS-mutant colorectal cancer
NSW
2031 - Randwick - Scientia Clinical Research Ltd
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
NCT06581432
Advanced
Phase 2
Recruiting
Beamion PANTUMOR-1: A Phase II, Multicentre, Multicohort, Open-label Trial to Evaluate the Efficacy and Safety of Oral Zongertinib (BI 1810631) for the Treatment of Selected HER2-mutated or Overexpressed/Amplified Solid Tumours (
1479-0009
)
ERBB2 inhibitor,second generation
Cervical cancer
Gastroesophageal junction adenocarcinoma
NOT Breast cancer
NOT Gastroesophageal cancer
NOT Squamous non-small-cell lung cancer
Non-small cell lung cancer
Solid tumour
Urothelial carcinoma
NSW
2065 - St Leonards - GenesisCare North Shore Private Hospital
2109 - North Ryde - Macquarie University Hospital
QLD
4102 - Woolloongabba - Princess Alexandra Hospital
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
WA
6008 - Subiaco - Bendat Family Comprehensive Cancer Centre - St John of God Subiaco Hospital
Additional search terms:
API and Webpage URLs:
Copy /Bookmark
Filters
Recruitment Status
Recruiting (4)
Recruitment Country and State
NSW (3)
VIC (2)
QLD (1)
SA (1)
WA (1)
Phase
Phase 1 (3)
Phase 2 (1)
Trial Type
Advanced (4)
Cancer Therapy Class
ERBB2
100%
EGFR
50%
MET
25%
CDK4
25%
CDK6
25%
ER
25%
PI3Kalpha
25%
VEGF
25%
oestrogen axis
25%
Facility
3000 - Melbourne - Peter MacCallum Cancer Centre (2)
2050 - Camperdown - Chris O'Brien Lifehouse (1)
2148 - Blacktown - Blacktown Hospital, Blacktown Cancer and Haematology Centre (1)
2031 - Randwick - Scientia Clinical Research Ltd (1)
2065 - St Leonards - GenesisCare North Shore Private Hospital (1)
2109 - North Ryde - Macquarie University Hospital (1)
4102 - Woolloongabba - Princess Alexandra Hospital (1)
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre (1)
6008 - Subiaco - Bendat Family Comprehensive Cancer Centre - St John of God Subiaco Hospital (1)
Cancer Type
Cancer
Lung cancer
Non-small cell lung cancer
Respiratory tract cancer
Solid tumour
Thoracic cancer
Gastrointestinal cancer
Breast adenocarcinoma
Breast cancer
Colorectal adenocarcinoma
Colorectal cancer
HER2-negative breast cancer
HER2-positive breast cancer
Lower gastrointestinal cancer
RAS-mutant colorectal cancer
Cervical cancer
Gastric cancer
Gastric carcinoma
Gastroesophageal cancer
Gastroesophageal junction adenocarcinoma
Gynaecological cancer
HPV-related cancer
HPV16-positive cancer
Oesophageal cancer
Upper gastrointestinal cancer
Urogenital cancer
Urothelial carcinoma
Viral-related cancer
URLs for this search
API URL:
Copy
Bookmarkable URL:
Copy